By modulating critical pathways (e.g., AKT/mTOR, JAK/STAT, and NRF2) in tandem with Tregs, MDSCs, and fibroblasts, it dampens tumor progression while enhancing chemotherapy responsiveness. Here, NFE2L2 is linked to neoplasm.